Frutinib 5 mg is a Product of the Generic Fruquintinib

What Is Frutinib 5 mg Indications and Uses?

Frutinib 5 mg (Fruquintinib) is a kinase inhibitor indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild type and medically appropriate, an anti-EGFR therapy.

Pharmacology (Source, Chemical and Physical Composition) Of Frutinib 5 mg

Frutinib 5 mg (Fruquintinib) is a small molecule kinase inhibitor of vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3 with IC50 values of 33, 35, and 0.5 nM, respectively. In vitro studies showed fruquintinib inhibited VEGF-mediated endothelial cell proliferation and tubular formation. In vitro and in vivo studies showed fruquintinib inhibited VEGF-induced VEGFR-2 phosphorylation. In vivo studies showed fruquintinib inhibited tumor growth in a tumor xenograft mouse model of colon cancer.

Dosage And Administration of Frutinib 5 mg

The recommended dose of Frutinib 5 mg (Fruquintinib) is 5 mg orally once daily for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. Take Fruquintinib with or without food at approximately the same time each day. Swallow the Fruquintinib capsule whole. Take a missed dose if less than 12 hours have passed since the missed scheduled dose. Do not take two doses on the same day to make up for a missed dose. Do not take an additional dose if vomiting occurs after taking Fruquintinib but continue with the next scheduled dose. Dose Modification : Recommended Dose Reductions for Fruquintinib. First dose reduction 4 mg orally once daily. Second dose reduction 3 mg orally once daily. Permanently discontinue Fruquintinib in patients unable to tolerate 3 mg orally once daily.

Drug Interactions of Frutinib 5 mg

Strong CYP3A Inducers : Avoid concomitant use of drugs that are strong CYP3A inducers with Frutinib 5 mg (Fruquintinib). Moderate CYP3A Inducers : If possible, avoid concomitant use of drugs that are moderate CYP3A inducers with Frutinib. If it is not possible to avoid concomitant use of a moderate CYP3A inducer and Frutinib, continue to administer Frutinib at the recommended dosage.

Side Effects of Frutinib 5 mg

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypertension Hemorrhagic Events Infections Gastrointestinal Perforation Hepatotoxicity Proteinuria Palmar-Plantar Erythrodysesthesia (PPE) Posterior Reversible Encephalopathy Syndrome (PRES)

Precautions And Warnings for Frutinib 5 mg

Hypertension : Frutinib 5 mg (Fruquintinib) can cause hypertension. Do not initiate Frutinib unless blood pressure is adequately controlled. Monitor blood pressure weekly the first month, at least monthly thereafter. Hemorrhagic Events : Frutinib can cause serious hemorrhagic events, which may be fatal. Permanently discontinue Frutinib in patients with severe or life-threatening hemorrhage. Infections : Frutinib can cause an increased risk of infections, including fatal infections.

Use During Pregnancy and Lactation

Pregnancy Risk Summary : Based on findings in animal studies and its mechanism of action, Frutinib 5 mg (Fruquintinib) can cause fetal harm when administered to a pregnant woman. Lactation Risk Summary : There are no data regarding the presence of fruquintinib or its metabolites in human milk or its effects on a breastfed child or on milk production. Females and Males of Reproductive: Females of childbearing potential and males with female partners of childbearing potential should use effective contraception during treatment and for 2 weeks after the last dose of Fruquintinib.

Storage Conditions of It

Do not store above 25°C. Protect from light. Keep out of the reach of children. Pack Image: Frutinib 5 mg Capsule Thanks for using MedEx! How would you rate your experience so far?